Peer Review History
| Original SubmissionMarch 9, 2020 |
|---|
|
PONE-D-20-06802 Hepatitis B virus prevalence and vaccine antibody titers in HIV exposed children in Botswana PLOS ONE Dear Dr Gaseitsiwe, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by May 29 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Heather B Jaspan Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type of consent you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). 3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access. We will update your Data Availability statement to reflect the information you provide in your cover letter. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Summary: This is a descriptive study reporting HBV specific antibody levels in 18-month-old HIV-exposed uninfected (HEU) infants in the Botswana setting. The manuscript shows that early immunization of infants induces antibody levels above the protective threshold in >90% of vaccine recipients, and in this cohort, no HBV infection were detected prompting good vaccine responses. The paper is well written, concise and scientifically sound and adds on existing literature regarding vaccine responses in HEU infants and thus is appropriate for this journal. Additional statistical analysis could be included to determine other factors that may be associated with infant antibody levels. Comments Introduction: 1. Line 69: strike out “exposure” Methods: 1. Description of infant demographics in the study need to be included in methods or the result section. 2. Authors should describe method for classification of infants as HEU even if mentioned in the parent study. 3. Line 90: mentions sample collection at 14-28 days after birth but HB titres were not measured at this time point – need additional information why this was not done. 4. Also, was there a reason for not measuring HB titres in mothers? 5. Re-phrase line 130-133, difficult to follow. 6. Consider rephrasing line 140. 7. Line 154 “the whole surface region…surface open reading frame (ORF) was used… Do you mean surface region of HBsAg Results: 1. No demographic description included for the children – give detail of median age at time of plasma sampling, did all infants receive all doses of the vaccine? 2. Line 164 - need a breakdown of when the infants received the vaccine – would this had correlated with antibody levels? 3. Consider re-phrasing line 165-168 for clarity. 4. Line 171 – The use of the word “about” is confusing, was 170 not the exact figure? 5. Was the range of antibody levels associated with timing of vaccination or collection of plasma samples? Are there any other maternal or infant factors associated with antibody levels e.g sex, maternal HIV viral load or CD4 levels. 6. No mention of antibody level testing in maternal samples. Discussion: 1. Line 221: difficult to determine protection in the absence of exposure. 2. Line 226: missing the word “vaccine” 3. Line 228-230: missing reference 4. Line 240: consider rephrasing to – “..not receiving the HBV primary vaccine dose at birth” 5. Line 243 Should be in the results section. Minor issues 1. “However” should be used to contrast preceding sentences or phrases and it’s use in Line 29, 66 and 81 is a bit misleading. 2. Double check for punctuation following in text reference inserts. 3. Line 172 – preference of the use “greater than” instead of “more than” Reviewer #2: Intro: Line 78: Will be helpful to mention the dosing (i.e. 6, 10 and 14week) of HBV vaccine Also, might be important to mention the Botswana guideline as respect breast feeding among HIV infected mothers Method: not clear how the samples were stored (i.e. storage condition of the samples). Information might be helpful to readers Result: According to your analysis in line 162, two hundred and twenty nine (75%) had timely vaccination while 75 didn’t (that give a total of 304 HEU). However, in line 165 to 168, you seem to analyse the data for 269 of the 304 HEU. So what about the other 35 HEU? It may be better to have a table to visual these key results rather than have them only in text. Why median age of mothers and not mean? Were the data not normally distributed? Could you explain this? Despite being a retrospective study, it will be great to have some demographic information about the children: birth weight, feeding pattern (i.e. breast fed or formula fed) etc. Or at the least, reference the original published work that reported these information if available. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Sonwabile Dzanibe Reviewer #2: Yes: OKPOKORO EVAEZI [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-06802R1 Hepatitis B virus prevalence and vaccine antibody titers in HIV exposed children in Botswana PLOS ONE Dear Dr. Gaseitsiwe, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that we can provisionally accept your submission for publication. However, I request that a few additional changes are made: Most importantly, please follow the NIAID HIV Language Guide Dated February 2020, and refer to "persons living with HIV" instead of HIV-positive as well as "Children HIV-exposed but uninfected" etc. Additionally, Table 1 needs some editing. Also there is not need to specify both % male AND percent female unless there were some infants with unassigned sex at birth (i.e. that the % does not add up to 100). Finally, line 177: "Mean" should not be capitalised as its in the middle of a sentence, and new-born should not be hyphenated (line 247). Please submit your revised manuscript by Aug 13 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Heather B Jaspan Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 2 |
|
Hepatitis B virus prevalence and vaccine antibody titers in children HIV exposed but uninfected in Botswana PONE-D-20-06802R2 Dear Dr. Gaseitsiwe, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Heather B Jaspan Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-20-06802R2 Hepatitis B virus prevalence and vaccine antibody titers in children HIV exposed but uninfected in Botswana Dear Dr. Gaseitsiwe: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Heather B Jaspan Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .